44
Views
26
CrossRef citations to date
0
Altmetric
Original Article

DNA Cell Content Studies in Multiple Myeloma

, , &
Pages 33-41 | Received 03 Dec 1995, Published online: 01 Jul 2009

References

  • Shankey T. V., Ravinovitch P. S., Bagwell B., Bauer K. D., Duque R. E., Hedley D. W., Mayall B. H., Wheeless L. L. Guidelines for implementation of clinical DNA cytometry. Cytometry 1993; 14: 472–477
  • Duque R. E., Andreef M., Braylan R. C., Diamond L. W., Peiper S. C. Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology. Cytometry 1993; 14: 492–496
  • Durie B. G. M. Cellular and molecular genetic features of myeloma and related disordes.(1992). Hematol. Oncol. Clin. N. Am. 1992; 6: 463–477
  • Latreille J., Barlogie B., Dosik G., Johnston D. A., Drewinko B., Alexanian R. Cellular contents as a marker of human multiple myeloma. Blood 1980; 55: 403–408
  • Bunn P. A., Krasnow S., Makuch R. W., Schlam M. L., Schechter G. P. Flow cytometric analysis of DNA content of bone marrow cells in patients with plasma cell Myeloma: Clinical implications. Blood 1982; 59: 528–535
  • Latreille J., Barlogie B., Johnston D. A., Drewinko B., Alexanian R. Ploidy and proliferative characteristics in monoclonal gammopathies. Blood 1982; 59: 43–51
  • Barlogie B., Alexanian R., Dixon D., Smith L., Smallwood L., Delasalle K. Prognostic implications of tumor cell DNA and RNA content in multiple myeloma. Blood 1985; 66: 338–341
  • Smith L., Barlogie B., Alexanian R. Biclonal and hypodiploid multiple myeloma. Am. J. Med. 1986; 80: 841–843
  • Morgan R. J., Gonchoroff N. J., Katzmann J. A., Witzig T. E., Kyle R. A., Greipp P. R. Detection of hypodiploidy using multi-parameter flow cytometric analysis: a prognostic indicator in multiple myeloma. Am. J. Hematol. 1989; 30: 195–200
  • Danova M., Riccardi A., Ucci G., Luoni R., Giordano M., Mazzini G. Ras oncogene expression and DNA content in plasma cell dyscrasias: a flow cytofluorimetric study. Br. J. Cancer 1990; 62: 781–785
  • Tafuri A., Meyers J., Lee B. J., Andreeff M. DNA and RNA flow cytometric study in multiple myeloma. Clinical correlations. Cancer 1991; 67: 449–454
  • Tienhaara A., Pelliniemi T. T. Flow cytometric DNA analysis and clinical correlations in multiple myeloma. Am. J. Clin. Pathol. 1991; 97: 322–330
  • Shimazaki C., Gotoh H., Ashihara E., Oku N., Inaba T., Murakami S., Itoh K., Ura Y., Nakagawa M., Fujita N. Immunophenotype and DNA contents of myeloma cells in primary plasma cell leukemia. Am. J. Hematol. 1992; 39: 159–162
  • Ucci G., Petrini M., Riccardi A. Expression of p170 protein in multiple myeloma: a clinical study. Hematol Oncol. 1992; 10: 213–20
  • Zandecki M., Bernardi F., LaÏ J. L., Facon T., Izydorczyk V., Bauters F., Cosson A. Image analysis in multiple myeloma at diagnosis. Correlation with cytogenetic study. Cancer Genet. Cytogenet. 1994; 14: 115–9
  • Benchaib M., Souchier C., Ffrench M., Remy F., Bryon P. A. Fluorescence image analysis of plasma cells in monoclonal gammopathies. Anal. Quant. Cytol. Histol. 1994; 16: 137–44
  • De Martinis M., Ginaldi L., D'Ostilio A., Marini A., Di Genaro A., Quaglino A. Simultaneous phenotypic and kinetic analysis in multiple myeloma. Thirty-sixth annual meeting of the ASH., Nashville, TN, December, 2–61994, Abstract 2595
  • Garcia-Sanz R., OrfÄO A., GonzÁLez M., Mora M. J., HernÁNdez J. M., Ortega F., Borrego D., Carnero M., Casanova F., JimÉNez R., Portero J. A., San Miguel J. F. Prognosic implications of DNA aneuploidy in a series of 156 untreated MM patients. Br. J. Haematol. 1995; 90: 106–112
  • Hedley D. W., Shankey T. V., Wheeless L. L. DNA Cytometry Consensus Conference. Cytometry 1993; 14: 471
  • OrfÃO A., GonzÁLez M., Ciudad J., LÓPez-Berges M. C., LÓPez A., Vidriales B., Macedo A., San Miguel J. F. Cell cycle and DNA aneuploidy: Biological bases and terminology. DNA cytometric analysis, A. Sampedro, A. OrfÃO. Ediciones de la Universidad de Oviedo, Oviedo 1993; 13–24
  • Cooke H. J., Hindley. Cloning of human satellite III DNA: different components are on differents chromosomes. J. Nucl. Acid. Res. 1979; 6: 3177–3197
  • Dewald G. W., Kyle R. A., Hicks G. A., Greipp P. R. P. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia or amyloidosis. Blood 1985; 66: 380–387
  • Facon T., Lai J. L., Nataf E., Preudhomme C., Zandecki M., Hammad M., Wattel E., Jouet J. P., Bauters F. Improved cytogenetic analysis of bone marrow plasma cells after cytokine stimulation in multiple myeloma: a report on 46 patients. Br. J. Haematol 1993; 84: 743–745
  • LaÏ J. L., Zandecki M., Mary J. Y., Bernardi F., Izydorczyk V., Flactif M., Morel P., Jouet J. P., Bauters F., Facon T. Improved cytogenetics in Multiple Mieloma. Blood 1995; 85: 2490–2497
  • Sawyer J. R., Waldron J. A., Jagannath S., Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet. Cytogenet. 1995, in press 1995
  • Lee W., Han K., Drut R. M., Harris C. P., Meisner L. F. Use of fluorescence in situ hybridization for retrospective detection of aneuploidy in multiple myeloma. Gen. Chromosom. Cancer 1993; 7: 137–43
  • Facon T., Flactif M., Zandecki M., Bernardi F., Bauters F., LaÏ J. L. (1994) Fluorescence in situ Hibridization improves the detection of cytogenetic abnormalities in multiple myeloma. Thirty-sixth annual meeting of the ASH., Nashville, TN, December, 2–61994, Abstract 2076
  • Sawyer J., Tricot G., Mattox S., Barlogie B. (1994) Monosomy 13 (-13) or abnormalities involving 14q (14q δ) are associated with poor prognosis in multiple myeloma. Thirty-sixth annual meeting of the ASH., Nashville, TN, December, 2–61994, Abstract 2078
  • Drach J., Angerler J., Schuster J. Interphase cytogenetic studies in multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS). Thirty-sixth annual meeting of the ASH., Nashville, TN, December, 2–61994, Abstract 677
  • Tabernero M. D., San Miguel J. F., GarcÍA-Sanz R., NÁJera M. L., GarcÍA-Isidoro M., PÉRez-SimÓN J. A., GonzÁLez M., Wiegant J., Raap A. K., OrfÃO A. Incidence of chromosome numerical changes in multiple myeloma. A FISH analysis using 15 chromosome specific probes, (Submitted)
  • Dimopoulos M. A., Palumbo A., Delasalle K. B., Alexanian R. Primary plasma cell leukemia. Br. J. Haematol. 1994; 88: 754–759
  • Drach J., Gattringer C., Glassl H., Drach D., Huber H. The biological significance of the KI-67 growth fraction in multiple myeloma. Hematol. Oncol. 1992; 10: 125–134
  • Van Camp B., Durie B. G. M., Spier C., De Waele M., Van Riet I., Vela E., Frutiger V., Richter L. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood 1990; 76: 377–382
  • San Miguel J. F., GonzÁLez M., GascÓN A., Moro M. J., HernÁNdez J. M., Ortega F., JimÉNez R., Guerras L., Romero M., Casanova F., Sanz M. A., SÁNchez J., Portero J. A., OrfÃO A. Immunophenotype heterogeneity of multiple myeloma: Influence on the biology and clinical course of the disease. Br J Haematol 1991; 77: 185–190
  • Durie B. G. M., Salmon S. E., Moon T. E. Pretreatment tumor mass, cell kinetics and prognostic in multiple myeloma. Blood 1980; 55: 364–369
  • Greipp P. R., Katzmann L. A., O'Fallon W. M., Kyle R. A. Value of beta-2-microglobulin levels and plasma cell labeling indices as prognostic factors in patients with newly diagnosed multiple myeloma. Blood 1988; 72: 219–223
  • Boccadoro M., Massaia M., Dianziani U., Pileri A. Multiple myeloma: biological and clinical significance of bone marrow plasma cell labeling index. Haematologica 1987; 72: 171–178
  • San Miguel J. F., Garcia-Sanz R., GonzÁLez M., Moro M. J., HernÁNdez J. M., Borrego D., Carnero M., Casanova F., Ortega F., JimÉNez R., Portero J. A., OrfÃO A. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995; 85: 448–455
  • Greipp P. R., Lust J. A., O'Fallon M., Katzmann J. A., Witzig T. E., Kyle R. A. Plasma cell labeling index and β2-microglobulin predict survival independent of tymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382–3387
  • Greipp P. R., Gaillard J. P., Klein B. (1994) Independent prognostic value for plasma cell labeling index (PCL1), immunofluorescence microscopy plasma cell percent (IMPCP), beta 2-microglobulin (B2M), soluble interleukin-6 receptor (sIL-6R) and C-reactive protein (CRP) in myeloma trial E9487. Thirty-sixth annual meeting of the ASH., Nashville, TN, December, 2–61994, Abstract, 1524
  • Riccardi A., Danova M., Wilson G. Cell kinetics in human malignancies studied with in vivo administration of bromod-eoxyuridine and flow cytometry. Cancer Res 1988; 48: 6238–6245
  • OrfÃO A., Ciudad J., GonzÁLez M., San Miguel J. F., GarcÍA A. R., LÓPez-Berges M. C., Ramos F., Del CaÑIzo M. C., RÍOs A., Sanz M., LÓPez-Borrasca A. Prognostic value of S-phase white blood cell count in B-cell chronic lymphocytic leukemia. Leukemia 1992; 6: 47–51
  • Vidriales M. B., OrfÃO A., LÓPez-Berges M. C., GonzÁLez M., Macedo A., Ciudad J., LÓPez A., GarcÍA M. A., HernÁNdez J., Borrego D., San Miguel J. F. Prognostic value of S-phase cells in AML patients. Br J Haematol 1995; 89: 342, 1995
  • OrfÃO A., GarcÍA-Sanz R., LÓPez-Berges M. C., Vidriales M. B., GonzÁLez M., San Miguel J. F. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. Cytometry 1994; 17: 332–339
  • Shimazaki C., Gotoh H., Oku N., Inaba T., Murakami S., Oku N., Itoh K., Ura Y., Nakagawa M., Fujita N. Detection of minimal residual myeloma cells by dual parameter analysis of DNA and cytoplasmic immunoglobulin. Acta Haematol. 1991; 85: 20–25

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.